Title : Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation.

Pub. Date : 2021 Feb

PMID : 33219754






12 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. osimertinib epidermal growth factor receptor Homo sapiens
2 Impact of the generation of EGFR-TKIs administered as prior therapy on the efficacy of osimertinib in patients with non-small cell lung cancer harboring EGFR T790M mutation. osimertinib epidermal growth factor receptor Homo sapiens
3 BACKGROUND: There are few studies that directly compare the effects of osimertinib on patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) T790M mutation between the generation of prior EGFR tyrosine kinase inhibitors (TKIs). osimertinib epidermal growth factor receptor Homo sapiens
4 BACKGROUND: There are few studies that directly compare the effects of osimertinib on patients with non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) T790M mutation between the generation of prior EGFR tyrosine kinase inhibitors (TKIs). osimertinib epidermal growth factor receptor Homo sapiens
5 METHODS: We retrospectively reviewed clinical data from the medical records of consecutive patients with advanced NSCLC who had developed resistance to first- or second-generation EGFR-TKIs due to EGFR T790M mutation and were subsequently treated with osimertinib at Juntendo University Hospital. osimertinib epidermal growth factor receptor Homo sapiens
6 RESULTS: A total of 38 patients with NSCLC harboring EGFR T790M mutation were treated with osimertinib. osimertinib epidermal growth factor receptor Homo sapiens
7 CONCLUSIONS: PFS of osimertinib was significantly longer in patients with NSCLC harboring EGFR T790M mutation after treatment with afatinib than in patients after treatment with first generation EGFR-TKIs. osimertinib epidermal growth factor receptor Homo sapiens
8 CONCLUSIONS: PFS of osimertinib was significantly longer in patients with NSCLC harboring EGFR T790M mutation after treatment with afatinib than in patients after treatment with first generation EGFR-TKIs. osimertinib epidermal growth factor receptor Homo sapiens
9 Additional mutations other than EGFR T790M may affect the efficacy of osimertinib treatment. osimertinib epidermal growth factor receptor Homo sapiens
10 KEY POINTS: Significant findings of the study: PFS of osimertinib was significantly longer in patients with NSCLC harboring EGFR T790M mutation after treatment with afatinib than in patients after treatment with first generation EGFR-TKIs. osimertinib epidermal growth factor receptor Homo sapiens
11 KEY POINTS: Significant findings of the study: PFS of osimertinib was significantly longer in patients with NSCLC harboring EGFR T790M mutation after treatment with afatinib than in patients after treatment with first generation EGFR-TKIs. osimertinib epidermal growth factor receptor Homo sapiens
12 WHAT THIS STUDY ADDS: Additional mutations other than EGFR T790M may affect the efficacy of osimertinib treatment. osimertinib epidermal growth factor receptor Homo sapiens